[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100633398":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":24,"centralContacts":28,"locations":24,"responsibleParty":38,"collaborators":24,"id":42,"slug":24,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":24,"eligibilityCriteria":47,"healthyVolunteers":43,"sex":48,"minAge":49,"maxAge":24,"enrollmentInfo":50,"targetDuration":24,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":24,"overallStatus":59,"whyStopped":24,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":24},{"fullName":5,"class":6},"Assiut University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Cryotherapy + Saline Injection (Placebo)","EXPERIMENTAL","Patients will receive a single session of intralesional cryotherapy followed by intralesional saline injection as a placebo. Saline injections will be repeated at 4-week intervals for a total of four sessions to maintain blinding and follow-up consistency with the experimental group. Patients and care providers are not blinded. Two independent blinded observers will evaluate scar characteristics using OSAS and VSS",[13],"Procedure: Intralesional Cryotherapy + Saline Injection",{"label":15,"type":10,"description":16,"interventionNames":17},"Cryotherapy + TAC\u002F5-FU Injection","Patients will receive a single session of intralesional cryotherapy followed immediately by intralesional injection of a combination of triamcinolone acetonide (TAC, 40 mg\u002FmL) and 5-fluorouracil (5-FU, 50 mg\u002FmL) in a ratio of 1:9. Further intralesional injections of TAC and 5-FU will be administered at 4-week intervals for a total of four sessions. Patients and care providers are not blinded. Two independent blinded observers will evaluate scar characteristics using OSAS and VSS.",[18],"Procedure: Intralesional Cryotherapy + TAC\u002F5-FU Injection",[20,25],{"type":21,"name":22,"description":11,"armGroupLabels":23,"otherNames":24},"PROCEDURE","Intralesional Cryotherapy + Saline Injection",[9],null,{"type":21,"name":26,"description":16,"armGroupLabels":27,"otherNames":24},"Intralesional Cryotherapy + TAC\u002F5-FU Injection",[15],[29,34],{"name":30,"role":31,"phone":32,"phoneExt":24,"email":33},"Hadeer Ali Abouelela","CONTACT","01092452868","hadeer.abouelela1997@gmail.com",{"name":35,"role":31,"phone":36,"phoneExt":24,"email":37},"Yasmin Moustafa Tawfiq","01006033331","yasminm.t@aun.edu.eg",{"type":39,"investigatorFullName":30,"investigatorTitle":40,"investigatorAffiliation":41,"oldNameTitle":24,"oldOrganization":24},"PRINCIPAL_INVESTIGATOR","MD Student \u002F Dermatology Department","Northwest Biotherapeutics","100633398",false,"NCT07526168","Intralesional Cryosurgery Alone Versus Combined With 5-FU and Triamcinolone for Keloids","Efficacy and Safety of Intralesional Cryosurgery Alone and in Combination With Intralesional 5-fluorouracil\u002FTriamcinolone Acetonide Injection for Treatment of Keloids: a Comparative Clinical Study","Inclusion Criteria:\n\n* Adult patients (≥18 years) with clinically diagnosed keloids .\n* Keloids of size 1-10 cm in greatest dimension .\n* Keloids of at least one year duration\n\nExclusion Criteria:\n\n* Females who are pregnant, planning pregnancy, or lactating .\n* Hypertrophic scars .\n* Chronic kidney or liver disease (relevant for 5-FU safety) .\n* Patients with active inflammation, infection, or ulcer at or around the keloid or Lesions suspicious for malignancy .\n* Patients who received any treatment for the same keloid in the past 12 months .\n* Immunosuppressed patients or those with chronic inflammatory diseases .","ALL","18 Years",{"count":51,"type":52},32,"ESTIMATED","INTERVENTIONAL",[55],"NA","evaluate the efficacy and safety of intralesional cryosurgery alone compared with intralesional cryosurgery combined with intralesional 5-fluorouracil and triamcinolone acetonide in the treatment of keloids.",[58],"Keloid","NOT_YET_RECRUITING","2026-04-10",{"date":62,"type":63},"2026-04-13","ACTUAL",{"date":65,"type":52},"2026-07-01",{"date":67,"type":52},"2027-08-01",{"name":5,"class":6}]